{"entity":{"id":"ccnd3","kind":"target","name":"CCND3","aka":["cyclin D3","G1/S-specific cyclin-D3"],"tldr":"CCND3 (G1/S-specific cyclin-D3) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 4 more.","summary":"Regulatory component of the cyclin D3-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase.\n\nCIViC holds 5 clinical evidence items and 0 assertions across 3 variants, naming Palbociclib. Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes affected pathway 0.61, literature 0.93, genetic association 0.00, somatic mutation 0.97, animal model 0.47). IntOGen calls it a driver in 5 cohorts (3 activating, 2 loss-of-function), covering Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:1585","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1585"},{"label":"UniProt P30281","url":"https://www.uniprot.org/uniprotkb/P30281/entry"},{"label":"NCBI Gene 896","url":"https://www.ncbi.nlm.nih.gov/gene/896"},{"label":"Ensembl ENSG00000112576","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000112576"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets","intogen"],"cancers":["non-hodgkin-lymphoma","leukaemia","breast-cancer","dlbcl","nsclc","burkitt-lymphoma","all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 5 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate.","Diseases the sources name that have no OnCo cancer page yet, so they are not linked: T-cell Lymphoblastic Leukaemia/lymphoma."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"CCND3","role":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:1585","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1585","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P30281","url":"https://www.uniprot.org/uniprotkb/P30281/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene CCND3","url":"https://civicdb.org/features/10","note":"5 evidence items, 0 assertions, 3 variants; diseases: T-cell Lymphoblastic Leukaemia/lymphoma, Diffuse Large B-cell Lymphoma, Lung Squamous Cell Carcinoma, Burkitt Lymphoma, Cancer (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000112576","url":"https://platform.opentargets.org/target/ENSG00000112576/associations","note":"association with cancer (MONDO_0004992) 0.65; per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.51, diffuse large B-cell lymphoma 0.55, non-Hodgkin lymphoma 0.69, breast cancer 0.53, leukaemia 0.54 (GraphQL API, CC0)"},{"label":"IntOGen CCND3","url":"https://www.intogen.org/search?gene=CCND3","note":"driver in 5 cohorts (Act 3, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"hgnc":"HGNC:1585","ensembl":"ENSG00000112576","uniprot":"P30281","entrez":"896","biology":"Regulatory component of the cyclin D3-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Component of the ternary complex, cyclin D3/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. Shows transcriptional coactivator activity with ATF5 independently of CDK4. Location: Nucleus; Cytoplasm (UniProt). Locus 6p21.1 (HGNC).","whereFound":["Non-Hodgkin lymphoma: Open Targets association 0.69 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL)","Leukaemia: Open Targets association 0.54 with leukaemia (MONDO_0005059)","Breast cancer: Open Targets association 0.53 with breast cancer (MONDO_0007254)","Diffuse large B-cell lymphoma: Open Targets association 0.55 with diffuse large B-cell lymphoma (MONDO_0018905); CIViC evidence names this disease","Non-small-cell lung cancer: CIViC evidence names this disease","Burkitt lymphoma: CIViC evidence names this disease; IntOGen driver in 2 cohorts (BL)"],"targetClass":"transcription","prevalence":[]},"route":"/targets/ccnd3/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"burkitt-lymphoma","kind":"cancer","name":"Burkitt lymphoma","route":"/cancers/burkitt-lymphoma/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}]}}